An observational study in Heart Failure and Obstructive Sleep Apnea (OSA), sponsored by Itshak Amsalem. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Itshak Amsalem · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Heart Failure with a site in Israel — 23 open to participants now, 29 under way, 7 of them phase 3. Heart Failure · Israel.
Among the 183 studies in Heart Failure with a site in Israel, this one is the 35th largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2026, is one of 47 observational ones, reaches primary completion later than 11 of the 28 other live ones, and was the 182nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →23 of the 183 studies in Heart Failure with a site in Israel are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Israel, Austria, Czechia and 4 more countries
Ages 18–99
Bayer · Sites in Israel, United States, Argentina and 20 more countries
Ages up to 18
Biotronik SE & Co. KG · Sites in Israel, Australia, Austria and 10 more countries
Ages 18+
Novo Nordisk A/S · Sites in Israel, United States, Argentina and 24 more countries
Ages 18+
Bayer · Sites in Israel, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 43 · Phase 4 10
First in 1983; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 260 across the 134 interventional studies, 150 across the 47 observational. Of the 116 that completed or were terminated, 43 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 183 have an industry lead sponsor. The 10 most frequent:
Itshak Amsalem is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Itshak Amsalem has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06682910Microtech Medical Technologies, LtdAssessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation | 2026-11 |
| NCT06851949Cardiac SuccessVsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure | 2026-12 |
| NCT06122779Bristol-Myers SquibbStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | 2026-12-14 |
| NCT07601724Itshak AmsalemThe Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure | 2027-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 183 studies in Heart Failure with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn how removing extra fluid from the body (diuresis) affects sleep apnea in adults hospitalized with heart failure.
The main questions it aims to answer are:
Does sleep apnea severity improve after fluid removal? Is the improvement in sleep apnea related to the amount of fluid removed? Do changes in neck size reflect changes in sleep apnea severity?
Participants admitted to the hospital with heart failure and fluid overload will take part in this study.
Participants will:
Use a wearable sleep monitoring device (WatchPAT) on the first night of hospitalization Use the device again after fluid removal, when the treating cardiologist determines that the patient is no longer fluid overloaded Have their neck circumference measured before and after fluid removal Have their weight and fluid balance recorded during hospitalization Have routine blood tests and clinical assessments as part of standard care
Researchers will compare each participant's results before and after fluid removal to see if sleep apnea improves and whether these changes are linked to fluid removal and changes in neck circumference.
Adults admitted with decompensated heart failure and clinical fluid overload, including both preserved and reduced ejection fraction. Participants will be recruited during hospitalization in a dedicated heart failure unit and followed prospectively with sleep monitoring and clinical assessments before and after achievement of clinical euvolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults hospitalized with heart failure and fluid overload who undergo standard diuretic therapy. Participants are evaluated using sleep monitoring (WatchPAT), neck circumference measurements, and clinical assessments before diuresis (on the first night of hospitalization) and after diuresis, when the treating cardiologist determines that the patient is no longer fluid overloaded.
Change in apnea-hypopnea index (AHI)
Change in obstructive sleep apnea severity, measured by the apnea-hypopnea index (AHI) using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
Time frame: From first night of hospitalization to achievement of clinical euvolemia (during hospitalization), up to 30-days.
Change in oxygen desaturation index (ODI)
Change in oxygen desaturation index (ODI) measured by the WatchPAT device between pre-diuresis and post-diuresis assessments
Time frame: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Change in respiratory disturbance index (RDI)
Change in respiratory disturbance index (RDI), defined as the number of respiratory disturbance events per hour of sleep, measured using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
Time frame: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Correlation between change in respiratory disturbance index (RDI) and body weight change
Correlation between the change in respiratory disturbance index (RDI), measured in events per hour using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
Time frame: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Correlation between change in apnea-hypopnea index (AHI) and body weight change
Correlation between the change in apnea-hypopnea index (AHI), defined as the number of apnea and hypopnea events per hour of sleep and measured using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
Time frame: From first night of hospitalization to achievement of clinical euvolemia, up to 30 days
Change in neck circumference
Change in neck circumference, measured in centimeters using a standardized measuring tape, between pre-diuresis (at admission) and post-diuresis assessment after the treating cardiologist determines that the participant is no longer fluid overloaded
Time frame: From admission to achievement of clinical euvolemia, up to 30 days
Correlation coefficient between change in neck circumference and change in apnea-hypopnea index (AHI)
Correlation coefficient (unitless) describing the relationship between change in neck circumference (centimeters) and change in apnea-hypopnea index (AHI), measured in events per hour using the WatchPAT device
Time frame: From admission to achievement of clinical euvolemia, up to 30 days
Plan to share: Undecided — Individual participant data (IPD) sharing is currently undecided. Any future data sharing will depend on institutional policies, ethical approvals, and applicable data protection regulations. If shared, only de-identified data will be made available to qualified researchers upon reasonable request.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 12 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Itshak Amsalem